Xtal has developed a suite of gene-to-structure discovery services that have a core of established and proven technologies whilst maintaining a rich resource of dynamic and active partnerships for cutting edge science and theory that can be quickly and seamlessly enabled for the richest tool set and result oriented research in our segment

XPRESS, XAMINE, and XPLORE form the core of our knowledge based services
and approaches. These three elements address cell and molecular biology, biochemistry, and biophysics respectively.

Our services were created as a technological 360 degree evaluation of candidate drug agents, to provide secondary and even tertiary validation of the MOA. We have devised programs and offerings that are specialized for start-ups, mid-sized, and large bio/pharma.